Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON MARC SCHOENFELD

Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery

NPI
1942647078
CMS profile
1102061
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,812.02

168 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,812.02 168

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 168 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON MARC SCHOENFELD

NPI 1942647078 · CMS profile ID 1102061

Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 168 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942647078?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON MARC SCHOENFELD, NPI 1942647078, CMS profile ID 1102061. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 168 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942647078?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JASON MARC SCHOENFELD, NPI 1942647078, CMS profile ID 1102061. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 168 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942647078?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JASON MARC SCHOENFELD, NPI 1942647078, CMS profile ID 1102061, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 168 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1942647078?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

168 matching records · $2,812.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 168 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 168.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $4.2409/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455447 CMS
LEO Pharma Inc. $24.3109/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936280661 CMS
PFIZER INC. $13.9709/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949572583 CMS
ABBVIE INC. $8.0308/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543757 CMS
Sebela Pharmaceuticals Inc. $17.1308/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898429139 CMS
Janssen Biotech, Inc. $32.0508/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455689 CMS
GENZYME CORPORATION $16.2108/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939062467 CMS
ABBVIE INC. $14.2108/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543755 CMS
ABBVIE INC. $25.5808/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543753 CMS
Janssen Biotech, Inc. $27.0808/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455499 CMS
Novartis Pharmaceuticals Corporation $23.5508/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894337429 CMS
Janssen Biotech, Inc. $29.5608/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455583 CMS
ABBVIE INC. $13.7808/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543751 CMS
Helsinn Therapeutics (U.S.), Inc. $15.8807/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904592289 CMS
Janssen Biotech, Inc. $39.1607/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455617 CMS
ABBVIE INC. $3.2507/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543749 CMS
Sun Pharmaceutical Industries Inc. $23.1407/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947791755 CMS
Novartis Pharmaceuticals Corporation $22.9307/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894337423 CMS
Janssen Biotech, Inc. $6.9707/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455495 CMS
LEO Pharma Inc. $23.3307/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936280655 CMS
ABBVIE INC. $14.7207/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543747 CMS
Janssen Biotech, Inc. $13.9207/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455383 CMS
Regeneron Healthcare Solutions, Inc. $14.2907/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927379221 CMS
PFIZER INC. $29.0407/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949626641 CMS
Janssen Biotech, Inc. $6.6507/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455391 CMS
Janssen Biotech, Inc. $32.5207/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455681 CMS
Janssen Biotech, Inc. $4.1207/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455471 CMS
ABBVIE INC. $14.6606/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543745 CMS
ABBVIE INC. $12.5506/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543743 CMS
Janssen Biotech, Inc. $14.5006/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455599 CMS
ABBVIE INC. $13.4206/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543741 CMS
ABBVIE INC. $8.4806/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543739 CMS
Janssen Biotech, Inc. $26.1006/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455657 CMS
Sun Pharmaceutical Industries Inc. $22.8906/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947791751 CMS
ABBVIE INC. $18.3106/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543737 CMS
Janssen Biotech, Inc. $14.2006/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455591 CMS
GENZYME CORPORATION $19.4206/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939062447 CMS
ABBVIE INC. $14.2106/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543735 CMS
Janssen Biotech, Inc. $37.7006/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455649 CMS
ABBVIE INC. $2.6306/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543733 CMS
Janssen Biotech, Inc. $20.6006/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455641 CMS
Janssen Biotech, Inc. $9.1306/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455531 CMS
Sun Pharmaceutical Industries Inc. $2.5206/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947791771 CMS
Janssen Biotech, Inc. $2.6605/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455633 CMS
Lilly USA, LLC $26.7505/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918120487 CMS
Janssen Biotech, Inc. $12.5005/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455375 CMS
Novartis Pharmaceuticals Corporation $14.0905/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894337419 CMS
Janssen Biotech, Inc. $5.5705/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886455712 CMS
ABBVIE INC. $17.0505/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891543731 CMS
PFIZER INC. $28.2705/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949582813 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,512.88 93
PY2020 $1,419.67 82
PY2021 $2,187.04 135
PY2022 $2,812.02 168
PY2023 $5,930.87 152
PY2024 $2,869.87 161
PY2025 $3,471.59 179

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $753,829.06 67
PY2024 Principal investigator $165,549.03 29
PY2023 Principal investigator $19,975.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $44,182.00 12/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422117
Principal investigator 1 SANOFI US SERVICES INC. $4,242.40 12/22/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132907
Principal investigator 1 SANOFI US SERVICES INC. $7,833.60 12/15/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132886
Principal investigator 1 ABBVIE INC. $183.33 12/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202529708
Principal investigator 1 ABBVIE INC. $700.65 12/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202529710
Principal investigator 1 SANOFI US SERVICES INC. $3,225.10 12/08/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132871
Principal investigator 1 ABBVIE INC. $35,815.62 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527458
Principal investigator 1 ABBVIE INC. $7,660.24 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527460
Principal investigator 1 SANOFI US SERVICES INC. $5,237.82 11/24/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132883
Principal investigator 1 SANOFI US SERVICES INC. $9,516.40 11/17/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132864
Principal investigator 1 ABBVIE INC. $23,239.15 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522653
Principal investigator 1 ABBVIE INC. $26,907.23 11/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520883
Principal investigator 1 Janssen Research & Development, LLC $20,340.00 10/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422149
Principal investigator 1 SANOFI US SERVICES INC. $43,495.50 10/20/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132847
Principal investigator 1 SANOFI US SERVICES INC. $2,327.22 10/14/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132837
Principal investigator 1 ABBVIE INC. $1,075.68 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202514153
Principal investigator 1 ABBVIE INC. $20,675.41 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202514155
Principal investigator 1 Janssen Research & Development, LLC $4,156.00 09/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422136
Principal investigator 1 SANOFI US SERVICES INC. $3,718.60 09/22/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132815
Principal investigator 1 SANOFI US SERVICES INC. $6,552.00 09/15/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132807
Principal investigator 1 Janssen Research & Development, LLC $33,814.00 09/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422098
Principal investigator 1 Janssen Research & Development, LLC $8,370.00 09/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422145
Principal investigator 1 SANOFI US SERVICES INC. $1,260.00 09/08/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132777
Principal investigator 1 ABBVIE INC. $13,539.78 09/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509932
Principal investigator 1 ABBVIE INC. $6,000.00 08/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202505853
Principal investigator 1 SANOFI US SERVICES INC. $562.00 08/25/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132812
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 08/18/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132768
Principal investigator 1 ABBVIE INC. $4,242.50 08/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202503169
Principal investigator 1 Janssen Research & Development, LLC $35,715.00 07/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422122
Principal investigator 1 SANOFI US SERVICES INC. $162.00 07/28/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132762
Principal investigator 1 ABBVIE INC. $6,000.00 07/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202499102
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132730
Principal investigator 1 SANOFI US SERVICES INC. $19,529.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132743
Principal investigator 1 SANOFI US SERVICES INC. $17,350.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132752
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132756
Principal investigator 1 ABBVIE INC. $3,798.31 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202494823
Principal investigator 1 ABBVIE INC. $21,417.25 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495457
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 07/02/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132748
Principal investigator 1 Janssen Research & Development, LLC $23,626.00 06/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422160
Principal investigator 1 ABBVIE INC. $1,135.07 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202489579
Principal investigator 1 ABBVIE INC. $5,437.08 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489809
Principal investigator 1 ABBVIE INC. $7,427.74 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202489811
Principal investigator 1 ABBVIE INC. $1,123.20 06/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487297
Principal investigator 1 Janssen Research & Development, LLC $28,946.00 05/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422154
Principal investigator 1 SANOFI US SERVICES INC. $17,449.00 05/27/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132699
Principal investigator 1 ABBVIE INC. $745.92 05/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202484317
Principal investigator 1 ABBVIE INC. $23,968.40 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482829
Principal investigator 1 ABBVIE INC. $8,084.59 05/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202481479
Principal investigator 1 SANOFI US SERVICES INC. $270.95 05/05/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132677
Principal investigator 1 ABBVIE INC. $11,550.58 04/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202470376
Principal investigator 1 ABBVIE INC. $7,632.20 04/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202470379
Principal investigator 1 SANOFI US SERVICES INC. $24,401.20 04/02/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132647
Principal investigator 1 SANOFI US SERVICES INC. $8,419.85 04/02/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132660
Principal investigator 1 SANOFI US SERVICES INC. $8,415.30 04/02/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132672
Principal investigator 1 SANOFI US SERVICES INC. $1,155.00 03/24/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132656
Principal investigator 1 ABBVIE INC. $11,090.60 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460703
Principal investigator 1 ABBVIE INC. $689.85 03/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202456821
Principal investigator 1 ABBVIE INC. $13,748.65 03/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202457649
Principal investigator 1 SANOFI US SERVICES INC. $8,954.90 02/24/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132582
Principal investigator 1 ABBVIE INC. $16,356.95 02/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202448262
Principal investigator 1 ABBVIE INC. $6,106.45 02/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202444937
Principal investigator 1 SANOFI US SERVICES INC. $16,100.00 02/04/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226132596
Principal investigator 1 SANOFI US SERVICES INC. $7,834.00 01/21/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132605
Principal investigator 1 SANOFI US SERVICES INC. $18,023.00 01/21/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226132609
Principal investigator 1 SANOFI US SERVICES INC. $18,256.00 01/21/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132613
Principal investigator 1 Eli Lilly and Company $2,000.00 01/10/2025 Non-covered Recipient Entity
WCG CLINICAL INC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187891786
Principal investigator 1 ABBVIE INC. $4,036.79 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202434767